17. Assessment of Recombinant Zoster Vaccine Second Dose Completion in the United States

BACKGROUND: Recombinant Zoster Vaccine (RZV) was licensed in the United States (US) in October 2017 for the prevention of herpes zoster in adults ≥ 50 years of age (YOA). The vaccine is administered in a two-dose sequence with a 2- to 6-month interval; however, the Center for Disease Control & P...

Descripción completa

Detalles Bibliográficos
Autores principales: Patterson, Brandon J, Chen, Chi-Chang, McGuiness, Catherine B, Glasser, Lisa I, Sun, Kainan, Buck, Philip O
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776021/
http://dx.doi.org/10.1093/ofid/ofaa439.062

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776021/
http://dx.doi.org/10.1093/ofid/ofaa439.062

Ejemplares similares